Quintiles Partners with Belgium Pharma Movetis in Commercialization Deal

Tuesday, February 2, 2010 06:50 AM

Quintiles has entered into a strategic alliance with Movetis to help sell the Belgium pharma company’s new gastrointestinal product.

The partnership calls for Quintiles to provide commercialization services, including sales support, market intelligence, consulting, regulatory and post-marketing pharmacovigilance in the U.K. and Germany.  The companies did not provide specific financial information about the agreement but said they plan to extend the partnership later this year to cover other European countries.

Movetis is a European pharma company focused on the development of drugs used to treat gastrointestinal diseases.

 “We are confident that our alliance with Quintiles will help drive our goal of becoming a successful European specialty GI company,” said Movetis CEO Dirk Reyn in a statement. “The launch of Resolor will be a key milestone as we continue to build on our expertise in bringing new GI drugs from discovery to marketing.”

Quintiles launched a revamped brand identity earlier this month, focused on what the company is calling “The New Health”—the rapidly changing pharma industry. This partnership with Movetis is an example of what the company hopes will result from its new branding effort, according to Quintiles.

 “This agreement is an example of how leading specialty pharma companies are building partnerships that extend beyond the traditional commercial sales organization model to manage risk, increase productivity, overcome complexity and demonstrate value to stakeholders in the New Health,” said Chris Pepler, senior vice president of global business development and operations for Quintiles.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

November 17

PPD, Medidata join their technologies for risk-based monitoring, adaptive trial design

ERT acquires eClinical Insights in "strategic combination" to gain cloud-based trial software platform, expertise

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs